Drug information of Meloxicam

Meloxicam

Drug group:

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve the symptoms of arthritis, primary dysmenorrhea, fever; and as an analgesic, especially where there is an inflammatory component.

Mechanism of effect

The mechanism of action of Meloxicam like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

Pharmacodynamic

Meloxicam has analgesic, anti-inflammatory, and antipyretic properties.

Pharmacokinetics

Absolute bioavailability = 89%. Meloxicam is extensively metabolized in the liver. Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extents in the urine and feces.

Dosage

Usual Adult Dose for Osteoarthritis
Oral Suspension and Tablets:
-Initial dose: 7.5 mg orally once a day
-Maintenance dose: 15 mg orally once a day in patients requiring additional analgesia
-Maximum dose: 15 mg orally once a day
Oral Capsules:
-Initial dose: 5 mg orally once a day
-Maintenance dose: 10 mg orally once a day in patients requiring additional analgesia
-Maximum dose: 10 mg orally once a day
Usual Adult Dose for Rheumatoid Arthritis
Oral Suspension and Tablets:
-Initial dose: 7.5 mg orally once a day
-Maintenance dose: 15 mg orally once a day in patients requiring additional analgesia
-Maximum dose: 15 mg orally once a day
Usual Pediatric Dose for Juvenile Rheumatoid Arthritis
2 years or older:
Oral Suspension: 0.125 mg/kg orally once a day
Maximum dose: 7.5 mg orally once a day
Oral Tablets:
60 kg or greater: 7.5 mg orally once a day

Alerts

1-Nonsteroidal anti-inflammatory drugs(NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.
2-NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.

Points of recommendation

1-Meloxicam can be administered without regard to timing of meals or concomitant administration of antacids.
2-Inform patients that the concomitant use of Meloxicam Tablets, USP with other NSAIDs or salicylates (e.g., diflunisal, salsalate) is not recommended due to the increased risk of gastrointestinal toxicity,

Pregnancy level

D


Ask a Pharmacist


User's questions
    No comments yet.